The Indian Pharmacopoeia Commission is introducing a mandatory monograph for semaglutide to ensure drug consistency. This move follows a surge in generic launches after the patent expiry in March 2026, aimed at curbing quality variations and counterfeit risks in the weight-loss drug market.
The Indian Pharmacopoeia Commission (IPC) is finalizing a standardized monograph for semaglutide, a major step to regulate the quality of the popular weight-loss drug. This move establishes a uniform benchmark for purity, potency, and testing that all domestic manufacturers must meet. Until now, pharmaceutical companies largely relied on their own internal standards to produce the drug, which has led to variations in product quality across the industry.
The regulatory push comes after the patent for the drug held by Novo Nordisk expired in India on March 20, 2026. Following this expiry, the domestic pharmaceutical market saw a rapid influx of generic alternatives. Over 30 companies, including major players like Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, Zydus Lifesciences, and Alkem Laboratories, have since received approvals to manufacture and sell their own versions of the drug.
While the expansion offered more options for patients, it also created significant challenges regarding quality control and consistency. The new IPC monograph is designed to act as a defensive barrier, not only standardizing local production but also providing state regulators with the legal tools to detect impurities and counterfeit products. This comes at a time when authorities like the Central Drugs Standard Control Organisation (CDSCO) have increased their surveillance of the supply chain following reports of tainted batches.
For investors and market observers, this development marks a shift in the generic semaglutide segment. The initial 'gold rush' phase, defined by a large number of companies launching brands to capture early market share, is now being replaced by a phase of regulatory consolidation. Companies with robust manufacturing capabilities that can easily meet these new, stricter quality requirements may have an advantage. Conversely, smaller players or those struggling with the complex manufacturing processes required for peptide-based drugs may face higher compliance costs.
Intense competition among the 30-plus manufacturers has already led to significant price reductions for patients, which continues to put pressure on profit margins across the sector. Investors may want to track how these new regulatory standards affect the operating costs of manufacturers, and whether the market sees consolidation as smaller players struggle to maintain quality while dealing with falling prices. The next major update will be the official inclusion of these standards in the Indian Pharmacopoeia, which will make compliance a mandatory requirement for all manufacturers in the country.